PA8801501A1 - ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA - Google Patents

ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA

Info

Publication number
PA8801501A1
PA8801501A1 PA20088801501A PA8801501A PA8801501A1 PA 8801501 A1 PA8801501 A1 PA 8801501A1 PA 20088801501 A PA20088801501 A PA 20088801501A PA 8801501 A PA8801501 A PA 8801501A PA 8801501 A1 PA8801501 A1 PA 8801501A1
Authority
PA
Panama
Prior art keywords
arylindenopirimidines
adenosine
receiver antagonists
antagonists
adenosine receiver
Prior art date
Application number
PA20088801501A
Other languages
English (en)
Spanish (es)
Inventor
C Shook Brian
F Jackson Paul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8801501A1 publication Critical patent/PA8801501A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PA20088801501A 2007-10-24 2008-10-23 ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA PA8801501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98224707P 2007-10-24 2007-10-24

Publications (1)

Publication Number Publication Date
PA8801501A1 true PA8801501A1 (es) 2009-05-15

Family

ID=40091927

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088801501A PA8801501A1 (es) 2007-10-24 2008-10-23 ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA

Country Status (12)

Country Link
US (1) US8017614B2 (cg-RX-API-DMAC7.html)
EP (1) EP2217575A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011500819A (cg-RX-API-DMAC7.html)
CN (1) CN101835759A (cg-RX-API-DMAC7.html)
AR (1) AR069009A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008317034A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008003131A1 (cg-RX-API-DMAC7.html)
PA (1) PA8801501A1 (cg-RX-API-DMAC7.html)
PE (1) PE20091344A1 (cg-RX-API-DMAC7.html)
TW (1) TW200934493A (cg-RX-API-DMAC7.html)
UY (1) UY31420A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009055308A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
US9238643B2 (en) 2010-09-06 2016-01-19 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Amide compounds
JP6042968B2 (ja) 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム パーキンソン病の処置方法
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
CA3256033A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127510A1 (en) 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
ATE429421T1 (de) 2003-10-03 2009-05-15 Ortho Mcneil Pharm Inc Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten

Also Published As

Publication number Publication date
CN101835759A (zh) 2010-09-15
PE20091344A1 (es) 2009-09-24
WO2009055308A1 (en) 2009-04-30
AU2008317034A1 (en) 2009-04-30
EP2217575A1 (en) 2010-08-18
CL2008003131A1 (es) 2010-02-19
JP2011500819A (ja) 2011-01-06
TW200934493A (en) 2009-08-16
UY31420A1 (es) 2009-04-30
US8017614B2 (en) 2011-09-13
AR069009A1 (es) 2009-12-23
US20090111827A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CR9891A (es) Ciclopropil aminas como moduladores del receptor de histamina h3
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
ECSP034884A (es) Ligandos del receptor de 5-ht y sus usos
CR20120282A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
PA8801501A1 (es) ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA
ECSP11010977A (es) Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas
CR20130209A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
BRPI0614397A2 (pt) compostos de pirimidina como moduladores de receptor de serotonina
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
PA8801401A1 (es) Arilindenopirimidinas y su uso como adenosina a2a
CL2008001007A1 (es) Compuestos derivados de furo[2,3-b] piridina, moduladores del receptor canabinoide-1; y su uso para tratar psicosis, deficit de memoria, trastornos cognitivos, entre otras enfermedades.
ECSP12011842A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS
CL2015000890A1 (es) Compuestos derivados de etinilo como moduladores de la actividad del receptor mglur5; proceso de obtencion; composicion farmaceutica que lo contiene; uso en el tratamiento de ansiedad, dolor, depresion, enfermedad de parkinson, entre otras.
ECSP12011840A (es) Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos
ECSP12011844A (es) 2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo